Biotech | March 20, 2024
Lonza to buy US biologics site from Roche for US$ 1.2 billion
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Lonza plans to invest approximately CHF 500 million to upgrade the facility
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Comprehensive clinical development programs being initiated for each investigational candidate
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Total transaction value of the divestment is Rs. 3,660 million
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Subscribe To Our Newsletter & Stay Updated
